Evidence mapPaperPMID 31063192Full record

ArticleAmerican journal of epidemiology2019

Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples.

Sara Lodi, Andrew Phillips, Jens Lundgren, Roger Logan, Shweta Sharma, Stephen R Cole, Abdel Babiker, Matthew Law, Haitao Chu, Dana Byrne and 21 more

Abstract readComparative Study
In one paragraph

Article in American journal of epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Signals were broadly positive for months, but never definitive: the tocilizumab story.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Sara LodiDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
Andrew PhillipsInstitute for Global Health, University College London, United Kingdom.
Jens LundgrenDepartment of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark.
Roger LoganDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Shweta SharmaDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
Stephen R Cole
Abdel BabikerMedical Research Council, Clinical Trials Unit in University College London, London, United Kingdom.
Matthew LawThe Kirby Institute, Sidney, Australia.
Haitao ChuDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
Dana ByrneDivision of Infectious Diseases, Department of Medicine, Cooper University Hospital, Cooper Medical School at Rowan University, New Jersey.
Andrzej HorbanMedical University of Warsaw, Department for Adult's Infectious Diseases, Warsaw, Poland.
Jonathan A C SterneDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina.
Kholoud PorterInstitute for Global Health, University College London, United Kingdom.
Caroline SabinInstitute for Global Health, University College London, United Kingdom.
Dominique CostagliolaINSERM, Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Sophie AbgrallINSERM, Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
John GillSouthern Alberta Clinic, Calgary, Canada.
Giota TouloumiNational and Kapodistrian University of Athens, Faculty of Medicine, Dept. of Hygiene, Epidemiology and Medical Statistics, Greece.
Antonio G PachecoPrograma de Computação Científica, Fundacao Oswaldo Cruz, Rio de Janeiro, Brasil.
Ard van SighemStichting HIV Monitoring, Amsterdam, the Netherlands.
Peter ReissStichting HIV Monitoring, Amsterdam, the Netherlands.
Heiner C BucherBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, University of Basel, Switzerland.
Alexandra Montoliu GiménezCentre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC), Badalona, Spain.
Inmaculada JarrinCentro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
Linda WittkopUniv. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France.
Laurence MeyerCHU de Bordeaux, Pôle de santé publique, Service d'information médicale, Bordeaux, France.
Santiago Perez-HoyosVall d'Hebrón Research Institute; Barcelona, Spain.
Amy JusticeYale University School of Medicine, New Haven, Connecticut.
James D NeatonDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
Miguel A HernánDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
INSIGHT START Study Group and the HIV-CAUSAL Collaboration

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · HARVARD UNIVERSITY (MEDICAL SCHOOL) · 2004 to 2025
$11.1M
UNC Center for AIDS Research Core F BiostatisticsP30AI050410 · UNIV OF NORTH CAROLINA CHAPEL HILL · 2001 to 2025
$10.9M
Yale Clinical and Translational Science AwardUL1TR001863 · YALE UNIVERSITY · 2025 to 2025
$9.9M
Providence/Boston Center for AIDS Research (CFAR)P30AI042853 · MIRIAM HOSPITAL · 1998 to 2025
$9.6M
Extended follow-up of randomized participants in the INSIGHT START trialU01AI136780 · NIAID · UNIVERSITY OF MINNESOTA · PI Birgit Grund, Cavan S. Reilly · 2023 to 2023
$2.0M
Dynamic Strategies for the clinical management of HIV diseaseR37AI102634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2023 to 2025
$1.3M
Medical Research Council MC_UU_12023/23Medical Research Council MR/M004236/1NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001863NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI102634NIAID NIH HHS R37 AI102634NIAID NIH HHS R56 AI102634NIAID NIH HHS U01 AI136780NIAID NIH HHS UM1 AI068641NIAID NIH HHS UM1 AI120197
6 · The paper itself

Abstract

Effect estimates from randomized trials and observational studies might not be directly comparable because of differences in study design, other than randomization, and in data analysis. We propose a 3-step procedure to facilitate meaningful comparisons of effect estimates from randomized trials and observational studies: 1) harmonization of the study protocols (eligibility criteria, treatment strategies, outcome, start and end of follow-up, causal contrast) so that the studies target the same causal effect, 2) harmonization of the data analysis to estimate the causal effect, and 3) sensitivity analyses to investigate the impact of discrepancies that could not be accounted for in the harmonization process. To illustrate our approach, we compared estimates of the effect of immediate with deferred initiation of antiretroviral therapy in individuals positive for the human immunodeficiency virus from the Strategic Timing of Antiretroviral Therapy (START) randomized trial and the observational HIV-CAUSAL Collaboration.

Indexed as

Epidemiologic MethodsObservational Studies as TopicRandomized Controlled Trials as TopicResearch DesignAdultAnti-Retroviral AgentsFemaleHIV InfectionsHumansMaleMiddle AgedAnti-Retroviral Agentsantiretroviral initiationcausal inferenceper-protocol effecttarget trial

Identifiers

PMID31063192
PMCPMC6670045

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.